Outcomes for heart failure (HF) patients remain suboptimal. No known therapy improves
mortality in acute HF and HF with preserved ejection fraction; the most recent HF trial results …

The age-adjusted prevalence of peripheral arterial disease in the US population was
estimated to approach 12% in 1985, and as the population ages, the overall population …

Increasing evidence shows that endothelial cells play critical roles in maintaining vascular
homeostasis, regulating vascular tone, inhibiting inflammatory response, suppressing lipid …

Background Sargramostim [recombinant human granulocyte-macrophage colony-
stimulating factor (rhu GM-CSF)] was approved by US FDA in 1991 to accelerate bone …

Flow cytometry has evolved over the past 30 y from a niche laboratory technique to a routine
tool used by clinical pathologists and immunologists for diagnosis and monitoring of patients …

The discovery of endothelial progenitor cells (EPCs) in human peripheral blood advanced
the field of cell-based therapeutics for many pathological conditions. Despite the lack of …

Rationale: Low circulating progenitor cell numbers and activity may reflect impaired intrinsic
regenerative/reparative potential, but it remains uncertain whether this translates into a …

OBJECTIVES: Cell therapy is a novel experimental treatment modality for patients with
critical limb ischemia (CLI) of the lower extremities and no other established treatment …

Importance Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF) for
improving walking ability in people with lower extremity peripheral artery disease (PAD) are …

Background Peripheral arterial disease (PAD) is a major health problem and in about 1% to
2% of patients the disease progresses to critical limb ischaemia (CLI). In a substantial …